Levothyroxine Sodium is a synthetic hormone replacement therapy that targets thyroid hormone receptors alpha and beta (TRα and TRβ) to supplement the body's deficient thyroid hormone levels. Its intravenous injectable formulation is an essential medicine used to treat patients with Myxedema Coma, a life-threatening endocrine emergency. It is recognized as the only standard treatment that saves patients' lives in emergency room or intensive care unit settings where oral administration is impossible and rapid hormone supplementation is needed. This FDA regulatory information update is a significant milestone in ensuring continued access to the treatment in emergency situations and promoting patient safety.

The NDA 202231, whose information has been updated, is a lyophilized powder formulation of Levothyroxine Sodium injection, which received FDA approval on June 24, 2011. This formulation requires reconstitution with saline before use, but it has been proven effective and safe in clinical practice for a long time and has served as a reference listed drug. It is also used as a benchmark for the entry of liquid RTU (Ready-To-Use) injections, such as NDA 210632 approved by Fresenius Kabi. The regulatory update of the existing formulation is meaningful in that it updates the expiration date and safety standards of the powder formulation, which still accounts for a significant portion of the hospital supply chain.

The rights to the aforementioned application are closely linked between Fresenius Kabi (Fresenius Kabi USA) and Endo (Endo, Inc.) for commercialization. Originally, APP Pharmaceuticals applied for the application, which was then acquired by Fresenius Kabi, and Endo (Endo, Inc.) plays a role as a distributor and labeler, contributing to the supply of generic drugs. Recently, Endo underwent a bankruptcy restructuring and re-launched with a new ticker symbol, NDOI, establishing a stable financial base, thereby alleviating concerns about the collapse of the essential drug supply chain. The collaboration between these two major generic partners is driving the prevention of monopolistic price increases and the maintenance of stable price competitiveness for thyroid hormone injections in the United States.

The global Levothyroxine market is estimated at approximately $1.6 billion to $4.3 billion by 2025-2026, with the intravenous injection market forming a niche market of approximately $50 million in 2023. Although Myxedema Coma is a rare disease, occurring in 1 in 1 million people, the mortality rate reaches up to 60%, so hospital pharmacies must always stock a certain amount of the drug. As a result, Endo and Fresenius Kabi can generate stable hospital sales based on high barriers to entry among a few competitors such as Zydus Lifesciences. The market oligopoly structure centered on companies that have completed regulatory compliance is expected to play a significant role in creating a stable cash cow for these companies in the long term.